Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice.
Epstein-Barr virus (EBV) evolved an episomal system for maintaining life-long, latent infection of human B lymphocytes. Circular episomes engineered from EBV components required for this latent form of infection have the capacity to persist in most types of replicating mammalian cells without DNA integration and the pitfalls of insertional mutagenesis. EBV episomes are typically transduced using low-efficiency methods. Here we present a method for efficient delivery of EBV episomes to nuclei of hepatocytes in living mice using a helper-dependent adenoviral vector and Cre-mediated recombination in vivo to generate circular EBV episomes following infection. Cre is transiently expressed from a hepatocyte-specific promoter so that vector generation and transgene expression are tissue specific. We show long-term persistence of the circularized vector DNA and expression of a reporter gene in hepatocytes of immunocompetent mice.
Gil
J S
JS
Molecular Biology Institute, Department of Microbiology, Immunology and Molecular Genetics, University of California-Los Angeles, 611 Young Drive E, Los Angeles, CA 90095-1570, USA.
Gallaher
S D
SD
Berk
A J
AJ
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001402:B-Lymphocytes / Q000378:metabolism; D002478:Cells, Cultured; D017930:Genes, Reporter; D006367:HeLa Cells; D022781:Hepatocytes / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D007121:Immunocompetence; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010957:Plasmids / Q000008:administration & dosage* / Q000737:chemistry; D014161:Transduction, Genetic; D019076:Transgenes / Q000235:genetics*
Mol Ther. 2008 Jun;16(6):1004-6
18500239
Mol Ther. 2001 Jan;3(1):28-35
11162308
J Virol. 2004 Jun;78(12):6556-66
15163748
Mol Ther. 2001 Aug;4(2):122-9
11482983
Biochem Biophys Res Commun. 2006 Jan 13;339(2):673-8
16316630
Gene Ther. 1996 Jun;3(6):503-12
8789800
Rev Med Virol. 2005 Jan-Feb;15(1):3-15
15386591
Gene Ther. 2008 Apr;15(8):553-60
18288209
Nat Biotechnol. 2001 Jun;19(6):582-5
11385466
J Gene Med. 2004 Apr;6(4):395-404
15079814
Gene. 1993 Dec 22;136(1-2):137-43
8293997
J Virol. 1999 Sep;73(9):7582-9
10438848
Curr Gene Ther. 2008 Aug;8(4):222-35
18691018
EMBO J. 2007 Oct 3;26(19):4252-62
17853891
J Virol. 2009 Apr;83(7):3249-57
19158239
Hum Gene Ther. 1996 Mar 20;7(5):637-45
8845389
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13565-70
8942974
Proc Natl Acad Sci U S A. 1975 Apr;72(4):1441-5
1055416
Gene Ther. 1995 Mar;2(2):151-5
7719932
Plasmid. 2007 Jul;58(1):1-12
17350094
Hum Gene Ther. 1999 Jul 20;10(11):1773-81
10446917
J Virol. 1998 Jan;72(1):180-90
9420214
Cell. 2008 Feb 8;132(3):397-409
18267072
Nature. 1985 Feb 28-Mar 6;313(6005):812-5
2983224
Neurotherapeutics. 2007 Oct;4(4):715-24
17920552